These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Schwid SR; Panitch HS Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202 [TBL] [Abstract][Full Text] [Related]
3. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial. Minagar A; Alexander JS; Schwendimann RN; Kelley RE; Gonzalez-Toledo E; Jimenez JJ; Mauro L; Jy W; Smith SJ Arch Neurol; 2008 Feb; 65(2):199-204. PubMed ID: 18071030 [TBL] [Abstract][Full Text] [Related]
4. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959 [TBL] [Abstract][Full Text] [Related]
6. [Effect of weekly intramuscular interferon beta-1a on MRI lesions in patients with relapsing multiple sclerosis]. Waubant E; Sloan R; Andersson PB; Goodkin D Rev Neurol (Paris); 1999; 155 Suppl 2():S20-3. PubMed ID: 10367321 [TBL] [Abstract][Full Text] [Related]
7. Early treatment trials with interferon beta in multiple sclerosis. Panitch HS Mult Scler; 1995; 1 Suppl 1():S17-21. PubMed ID: 9345392 [TBL] [Abstract][Full Text] [Related]
8. [Natural interferon-beta in the treatment of relapsing-remitting multiple sclerosis: a multicenter, randomized, MRI-based, phase II clinical trial]. Fernández O; Antigüedad A; Arbizu T; Burgués S; Capdevila A; de Castro P; Correa de Sá JC; García-Merino JA; Izquierdo G; Magalhaes A; Montalbán X; Zarranz JJ Rev Neurol; 1999 Dec 16-31; 29(12):1093-9. PubMed ID: 10652728 [TBL] [Abstract][Full Text] [Related]
9. [A short history of beta-interferon therapy of multiple sclerosis]. Stock G; Horowski R Med Klin (Munich); 2001 Sep; 96 Suppl 1():3-9. PubMed ID: 11603113 [TBL] [Abstract][Full Text] [Related]
10. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Stone LA; Frank JA; Albert PS; Bash C; Smith ME; Maloni H; McFarland HF Ann Neurol; 1995 May; 37(5):611-9. PubMed ID: 7755356 [TBL] [Abstract][Full Text] [Related]
11. The use of interferon beta in relapsing-remitting multiple sclerosis. Etheridge LJ; Beverley DW; Ferrie C; McManus E Arch Dis Child; 2004 Aug; 89(8):789-91. PubMed ID: 15269086 [TBL] [Abstract][Full Text] [Related]
12. Dose and frequency of interferon treatment matter--INCOMIN and OPTIMS. Durelli L J Neurol; 2003 Dec; 250 Suppl 4():IV9-IV14. PubMed ID: 14712396 [TBL] [Abstract][Full Text] [Related]
13. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study. Schwid SR; Thorpe J; Sharief M; Sandberg-Wollheim M; Rammohan K; Wendt J; Panitch H; Goodin D; Li D; Chang P; Francis G; ; Arch Neurol; 2005 May; 62(5):785-92. PubMed ID: 15883267 [TBL] [Abstract][Full Text] [Related]
17. Safety and tolerability in relapsing-remitting multiple sclerosis patients treated with high-dose subcutaneous interferon-beta by Rebiject autoinjection over a 1-year period: the CoSa study. Lugaresi A; Durastanti V; Gasperini C; Lai M; Pozzilli C; Orefice G; Sotgiu S; Pucci E; Ardito B; Millefiorini E; Clin Neuropharmacol; 2008; 31(3):167-72. PubMed ID: 18520983 [TBL] [Abstract][Full Text] [Related]
18. [The role of interferon beta in the treatment of multiple sclerosis]. Seeldrayers P Rev Med Brux; 1999 Sep; 20(4):A264-7. PubMed ID: 10523902 [TBL] [Abstract][Full Text] [Related]
19. Effect of dose and frequency of interferon beta-1a administration on clinical and magnetic resonance imaging parameters in relapsing-remitting multiple sclerosis. Cocco E; Marchi P; Floris G; Mascia MG; Deriu M; Sirca A; Mamusa E; Lai M; Mura M; Mallarini G; Marrosu MG Funct Neurol; 2006; 21(3):145-9. PubMed ID: 17049133 [TBL] [Abstract][Full Text] [Related]
20. [Experience in the treatment of multiple sclerosis with interferon beta in Galicia]. Romero-López J; Seijo-Martínez M; Del Campo V; Amigo-Jorrín MC; Arias M; Cortés-Laíño JA; Dapena-Bolaño D; López-González FJ; Lorenzo-González JR; Marín-Sánchez M; Muñoz-García D; Ozaita-Arteche G; Prieto JM Rev Neurol; 2003 Dec 1-15; 37(11):1001-4. PubMed ID: 14669137 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]